Sep 2026· Advancement of science· 0 citations· 51 references
Medicine
TL;DR
MethyAnno is proposed as an interpretable deep metric learning framework that leverages multi‐scale information for accurate cell type annotation of scDNAm data and establishes MethyAnno as a robust and biologically interpretable tool for accurate cell type annotation and downstream epigenetic analysis.
Abstract
ABSTRACT Single‐cell DNA methylation (scDNAm) sequencing provides unique insights into epigenetic heterogeneity and cell‐specific regulatory landscapes. However, accurate cell type annotation for scDNAm data remains challenging, as the distinct data distribution of scDNAm hinders the adaptation of annotation methods from other omics, and specialized annotation tools for scDNAm are currently lacking. Here, MethyAnno is proposed as an interpretable deep metric learning framework that leverages multi‐scale information for accurate cell type annotation of scDNAm data. Additionally, MethyAnno enables generalized category discovery in open‐set scenarios by utilizing density‐based clustering to automatically estimate the number of novel cell types, while simultaneously deciphering cell‐type‐specific epigenetic signatures for biological interpretability. Extensive experiments demonstrate that MethyAnno excels in cross‐dataset annotation and novel type discovery, showing exceptional robustness in few‐shot scenarios for rare cell types. Moreover, interpretability analysis in the human brain dataset correctly recovers the genetic link between Sst interneurons and epilepsy heritability, the association of OPC cells with Alzheimer's disease, as well as the regulatory role of Pvalb cells in synaptic plasticity. Taken together, these findings establish MethyAnno as a robust and biologically interpretable tool for accurate cell type annotation and downstream epigenetic analysis.
Using standardized oracle inputs and Cohen’s κ, it is found that, within the ranges tested, the major paradigms achieved comparable accuracy, and the field’s near-term gains lie in strengthening infrastructure—prioritizing tool accessibility, standardized evaluation, and robustness to pipeline variation.
Oliver Wardhana, Zi-Yu Zeng, Xin Lu· bioRxiv· 0 citations
ABSTRACT Multi‐omics technologies generate high‐dimensional molecular signatures that provide unprecedented opportunities to uncover biological mechanisms. However, translating complex molecular alterations into coherent and interpretable functional insights remains a major challenge. Existing module discovery methods...
Yi-Fei Ge, Fei-Fan Zhang, Yi-Jiang Liu et al.· Advancement of science· 0 citations
Single-cell RNA sequencing profiles cellular heterogeneity at atlas scale, making automated annotation essential. However, target datasets often contain novel cell types missing from incomplete references. We present scOLAR, an ontology-guided open-set framework that learns prototypes over the Cell Ontology and uses bo...
GEOMeta provides a scalable resource and reproducible framework for metadata curation in the Gene Expression Omnibus, and benchmarked transcriptome representation models for predicting sex, age, tissue and disease from transcriptome embeddings.
Xiaodan Zhang, S. Paithankar, Jing Pu et al.· bioRxiv· 0 citations
Abstract Identification of new cell subtypes in single-cell RNA sequencing (scRNA-seq) data is critically crucial in accurately understanding the mechanisms of disease occurrence and development, which provides unprecedented insights into the development of therapeutic strategies, however, despite the abundance of exis...
Yue Yao, Xin Shao, Ren-Jie Chen et al.· Briefings in Bioinformatics· 0 citations
CARA is introduced, a cross-omics Bayesian framework that transfers cell type knowledge from scRNA-seq to scATAC-seq and detects novel cell types in single-cell DNA methylation data, demonstrating seamless extensibility to new modalities.
Lan Cao, Wenhao Zhang, Feng Zhou et al.· Genome Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.